+86-531-88916568
FDA approved a SBECD (Betadex sulfobutyl ether sodium) fosphenytoin sodium for injection
Home » News » FDA approved a SBECD (Betadex sulfobutyl ether sodium) fosphenytoin sodium for injection

FDA approved a SBECD (Betadex sulfobutyl ether sodium) fosphenytoin sodium for injection

Views:0     Author:Site Editor     Publish Time: 2021-01-04      Origin:Site

Phosphenytoin is used to prevent and treat seizures. Phosphoenytoin sodium encapsulated with betadex sulfobutyl ether sodium (SBEBCD) can maximize the safety of administration and improve the solubility, stability and bioavailability of the active pharmaceutical ingredient (API).  SESQUIENT™ (fosphenytoin sodium for injection) is the only FDA-approved room-temperature stable formulation of fosphenytoin sodium. It is FDA approved for adult and pediatric use in the U.S. to treat generalized tonic-clonic status epilepticus, the prevention and treatment of seizures occurring during neurosurgery and for substitution short-term use in place of oral phenytoin, when oral phenytoin administration is not possible.


The betadex sulfobutyl ether sodium (SBEBCD) (DMF record number 030167) produced by Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. has been jointly declared with pharmaceutical companies and will be activated soon.

Please contact with us if you want to get more information.

+86 531 88916568


20210103

PRODUCT CATEGORY

QUICK LINKS

CONTACT INFORMATION

Tel: +86-531-88916568
 Mail: enquiry@cydextrin.com
​​​​​​​ Address: Boxing Economic Development Zone, Binzhou, Shandong, China.

FREE CONSULTATION

Contact us
© 2020 Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. All rights reserved. Sitemap